Clinical Trial Update: Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating recombinant human neuregulin-1 for efficacy in cardiac remodeling in stable chronic systolic heart failure was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systolic Heart Failure

Drugs mentioned

• recombinant human neuregulin-1β (neuregulin-1β)

Snippet

Sponsor: Zensun Sci. & Tech. Co., Ltd. | Conditions: Chronic Systolic Heart Failure | Phase 3 | Status: TERMINATED